1. Guidance: Drug Safety Information – FDA's Communication to the Public.https://www.fda.gov/media/83097/download. Accessed July 31 2021.
2. Previous Drug Safety Communications:https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications. Accessed July 31 2021.
3. US Department of Health and Human Services Food and Drug Administration.FDA Drug Safety Communication: Risk of Next‐morning Impairment After use of Insomnia Drugs; FDA Requires Lower Recommended Doses for Certain Drugs Containing Zolpidem (Ambien Ambien CR Edluar and Zolpimist).2013.https://www.fda.gov/media/84992/download. Accessed July 31 2021.
4. US Department of Health and Human Services Food and Drug Administration.FDA Drug Safety Communication: FDA Approves New Label Changes and Dosing for Zolpidem Products and a Recommendation to Avoid Driving the Day After Using Ambien CR.2013.https://www.fda.gov/Drugs/DrugSafety/ucm352085.htm. Accessed July 31 2021.
5. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem